(MNKD) MannKind - Overview
Stock: Inhaled Insulin, Insulin Pump, Pulmonary Device, Antibiotic, Antifibrotic
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.9% |
| Relative Tail Risk | -9.22% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.22 |
| Alpha | -7.99 |
| Character TTM | |
|---|---|
| Beta | 0.552 |
| Beta Downside | 0.526 |
| Drawdowns 3y | |
|---|---|
| Max DD | 54.03% |
| CAGR/Max DD | 0.07 |
Description: MNKD MannKind January 18, 2026
MannKind Corp (NASDAQ: MNKD) is a U.S. biopharma focused on inhaled-delivery therapeutics for endocrine and orphan lung diseases, with its flagship product Afrezza – an inhaled insulin powder approved for adult diabetes management.
Beyond Afrezza, MannKind markets the V-Go wearable insulin pump and Tyvaso DPI (in partnership with United Therapeutics) for pulmonary arterial hypertension, and co-promotes Amphastar’s Baqsimi nasal glucagon.
The pipeline features MNKD-101 (nebulized clofazimine) in Phase 3 for nontuberculous mycobacterial lung disease, MNKD-201 (dry-powder nintedanib) in Phase 1 for idiopathic pulmonary fibrosis, MNKD-301 (pre-clinical) for cystic fibrosis, and a Phase 3 pediatric Afrezza trial targeting type 1 diabetes.
Strategic collaborations extend Afrezza’s reach into Brazil (Biomm) and India (Cipla), while licensing agreements with United Therapeutics and Thirona support Tyvaso DPI development and pulmonary-fibrosis research, respectively.
Key metrics (FY 2023): net revenue ≈ $22 M, driven primarily by Afrezza; cash & short-term investments ≈ $70 M, giving roughly 12 months of runway at current burn; and a 12-month forward-looking sales CAGR of ~-15 % for Afrezza, reflecting competitive pressure from newer GLP-1 agents. Sector-wide, the global diabetes therapeutics market exceeds $50 B and is expanding ~8 % YoY, while inhaled-drug delivery is projected to grow >10 % CAGR through 2030, driven by patient-preference for non-injectable options.
For a deeper, data-driven assessment of MNKD’s valuation assumptions, you may find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 29.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.52 > 1.0 |
| NWC/Revenue: 79.58% < 20% (prev 95.64%; Δ -16.07% < -1%) |
| CFO/TA 0.10 > 3% & CFO 48.7m > Net Income 29.2m |
| Net Debt (98.6m) to EBITDA (73.1m): 1.35 < 3 |
| Current Ratio: 3.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (311.6m) vs 12m ago 9.46% < -2% |
| Gross Margin: 75.18% > 18% (prev 0.72%; Δ 7446 % > 0.5%) |
| Asset Turnover: 65.45% > 50% (prev 57.56%; Δ 7.89% > 0%) |
| Interest Coverage Ratio: 1.97 > 6 (EBITDA TTM 73.1m / Interest Expense TTM 31.6m) |
Altman Z'' -15.00
| A: 0.50 (Total Current Assets 358.8m - Total Current Liabilities 109.1m) / Total Assets 494.6m |
| B: -6.43 (Retained Earnings -3.18b / Total Assets 494.6m) |
| C: 0.13 (EBIT TTM 62.4m / Avg Total Assets 479.4m) |
| D: -5.89 (Book Value of Equity -3.18b / Total Liabilities 539.2m) |
| Altman-Z'' Score: -22.96 = D |
Beneish M -3.21
| DSRI: 0.88 (Receivables 18.9m/18.2m, Revenue 313.8m/267.2m) |
| GMI: 0.96 (GM 75.18% / 71.91%) |
| AQI: 0.77 (AQ_t 0.08 / AQ_t-1 0.11) |
| SGI: 1.17 (Revenue 313.8m / 267.2m) |
| TATA: -0.04 (NI 29.2m - CFO 48.7m) / TA 494.6m) |
| Beneish M-Score: -3.21 (Cap -4..+1) = AA |
What is the price of MNKD shares?
Over the past week, the price has changed by +0.00%, over one month by +2.85%, over three months by +1.40% and over the past year by +2.30%.
Is MNKD a buy, sell or hold?
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MNKD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.4 | 63.3% |
| Analysts Target Price | 9.4 | 63.3% |
| ValueRay Target Price | 5.5 | -4.2% |
MNKD Fundamental Data Overview February 03, 2026
P/E Forward = 82.6446
P/S = 5.6563
P/EG = -0.23
Revenue TTM = 313.8m USD
EBIT TTM = 62.4m USD
EBITDA TTM = 73.1m USD
Long Term Debt = 73.4m USD (from longTermDebt, last quarter)
Short Term Debt = 49.0m USD (from shortTermDebt, last quarter)
Debt = 226.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 98.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.52b USD (1.56b + Debt 226.0m - CCE 260.0m)
Interest Coverage Ratio = 1.97 (Ebit TTM 62.4m / Interest Expense TTM 31.6m)
EV/FCF = 35.22x (Enterprise Value 1.52b / FCF TTM 43.2m)
FCF Yield = 2.84% (FCF TTM 43.2m / Enterprise Value 1.52b)
FCF Margin = 13.78% (FCF TTM 43.2m / Revenue TTM 313.8m)
Net Margin = 9.32% (Net Income TTM 29.2m / Revenue TTM 313.8m)
Gross Margin = 75.18% ((Revenue TTM 313.8m - Cost of Revenue TTM 77.9m) / Revenue TTM)
Gross Margin QoQ = 75.40% (prev 73.12%)
Tobins Q-Ratio = 3.08 (Enterprise Value 1.52b / Total Assets 494.6m)
Interest Expense / Debt = 3.25% (Interest Expense 7.33m / Debt 226.0m)
Taxrate = 9.60% (2.93m / 30.5m)
NOPAT = 56.4m (EBIT 62.4m * (1 - 9.60%))
Current Ratio = 3.29 (Total Current Assets 358.8m / Total Current Liabilities 109.1m)
Debt / Equity = -5.07 (negative equity) (Debt 226.0m / totalStockholderEquity, last quarter -44.6m)
Debt / EBITDA = 1.35 (Net Debt 98.6m / EBITDA 73.1m)
Debt / FCF = 2.28 (Net Debt 98.6m / FCF TTM 43.2m)
Total Stockholder Equity = -59.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.10% (Net Income 29.2m / Total Assets 494.6m)
RoE = -49.33% (negative equity) (Net Income TTM 29.2m / Total Stockholder Equity -59.3m)
RoCE = 440.5% (EBIT 62.4m / Capital Employed (Equity -59.3m + L.T.Debt 73.4m))
RoIC = -1185 % (out of range, set to none) (NOPAT 56.4m / Invested Capital -4.76m)
WACC = 7.31% (E(1.56b)/V(1.78b) * Re(7.95%) + D(226.0m)/V(1.78b) * Rd(3.25%) * (1-Tc(0.10)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.91%
[DCF Debug] Terminal Value 73.47% ; FCFF base≈37.5m ; Y1≈24.6m ; Y5≈11.2m
Fair Price DCF = 0.49 (EV 250.3m - Net Debt 98.6m = Equity 151.8m / Shares 307.1m; r=7.31% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 86.60 | EPS CAGR: 74.93% | SUE: -0.91 | # QB: 0
Revenue Correlation: 88.87 | Revenue CAGR: 65.15% | SUE: 0.46 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.07 | Chg30d=+0.020 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.15 | Chg30d=+0.077 | Revisions Net=-1 | Growth EPS=-24.1% | Growth Revenue=+23.2%